ReviewCurrent pharmaceutical design2025
Solid Lipid Nanoparticles for the Management of Hypertension: Advancements and Challenges.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cardiovascular diseases (CVDs) remain a global health challenge, with hypertension emerging as a leading risk factor. Hypertension, characterized by elevated arterial blood pressure (BP), significantly increases the risk of stroke and other CVDs. Despite advancements in antihypertensive medication, the effectiveness of hypertension treatment is often hindered by poor bioavailability and limited drug efficacy. In this quest, nanoparticles (NPs) offer a promising avenue for addressing the limitations associated with conventional antihypertensive drugs in hypertension treatment. Among several NPs, solid lipid nanoparticles (SLNs) have emerged as a potential candidate, presenting a multifaceted approach to revolutionize drug delivery within this domain. SLNs, characterized by a lipophilic matrix and stabilized by surfactants, offer scalability and compatibility with biological systems compared to several polymer-based nanosystems. By encapsulating antihypertensive drugs, SLNs enhance drug solubility and bioavailability and provide sustained release, thereby improving treatment efficacy. In this context, this review provides an overview of the pathophysiology of hypertension and the role of SLNs in drug delivery. Various preparation techniques of SLNs are discussed, highlighting their versatility and potential in pharmaceutical applications. Furthermore, the role of SLNs in the management of hypertension is thoroughly examined, with a focus on enhancing the physicochemical properties of antihypertensive drugs. Overall, SLNs represent a promising strategy for optimizing hypertension treatment by addressing the limitations of conventional drug delivery systems. By enhancing drug stability, bioavailability, and efficacy, SLNs offer new possibilities for improving patient outcomes and reducing the global burden of cardiovascular diseases. This review aims to contribute to the ongoing research and development of innovative therapies for hypertension management.
Indexed as
Identifiers
40108484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.